Relationship between K-ras mutation and the expression of p21 WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma

Neoplasma

Volumn 50, Issue 5, 2003, Pages 319-325

  Hermanova M ^a   Lukas Z ^a   Kroupova Z ^a   Kleibl, Z ^b   Novotny J ^c   Nenutil, R ^a   Pazourkova M ^a   Brazdil J ^a   Kren L ^a   Dite P ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

K ras; p53; Pancreatic intraepithelial neoplasia

Indexed keywords

K RAS PROTEIN; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CHRONIC PANCREATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 10744227680     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. ALMOGUERA C, SHIBATA D, FORRESTER K, MARTIN J, ARNHEIM N, PERUCHO M. Most human carcinoma of the exocrine pancreas contain mutant c-K-ras gene. Cell 1988; 53: 549-554.
2. APPLE SK, HECHT JR, LEWIN DN, JAHROMI SA, GRODY WW, NIERBERG RK. Immunohistochemical evaluation of K-ras, p53 and HER-2/neu expression in hyperplastic, dysplastic and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 1999; 30: 123-129.
3. BARTON CM, STADDON SL, HUGHES CM, HALL PA, O'SULLIVAN C, KLOPPEL G, THEIS B, RUSSELL RC, NEOTOLEMOS J, WILLIAMSON RC. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-1082.
4. WAF1/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61: 8830-8837.
5. BOS JL. Ras oncogenes in human cancer: a rewiev. Cancer Res 1989; 49: 4682-4689.
6. BOS JL, FEARON ER, HAMILTON SR, VERLAAN-DE VRIES M, VAN BOOM JH, VAN DER EB AJ, VOGELSTEIN B. Prevalence of ras gene mutations in human colorectal cancer. Nature 1987; 327: 293-297.
7. CHANG F, MCCUBREY JA. p21 (Cip1) induced by Raf is associated with increased Cdk4 activity in hemopoietic cells. Oncogene 2001; 20: 4354-4364.
8. DAY JD, DIGIUSEPPE JA, YEO C, LAI-GOLDMAN M, ANDERSON SM, GOODMAN SN, KERN SE, HRUBAN RH. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27: 119-124.
9. DIGIUSEPPE JA, YEO CJ, HRUBAN RH. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Advances in Anatomic pathology 1996; 3: 139-155.
10. DIGIUSSEPPE JA, REDSTON MS, YEO CJ, KERN SE, HRUBAN RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Surg Pathol 1995; 147: 884-888.
11. EL-DEIRY WS, HARPER JW, O'CONNOR PM, VELCULESCU VE, CANMAN CE, JACKMAN J, PIETENPOL JA, BURREL M, HILL DE, WANG Y, WIMAN KG, MERCER WE, KASTAN MB, KOHN KW, ELLEDGE SJ, KINZLER KW, VOGELSTEIN B. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
12. FINKEL E. High hopes for p21 in cancer treatment. Lancet 1996; 347: 1034.
13. FURUYA N, KAWA S, AKAMUTSU T, FURIHATA K. Long-term follow-up of patients with chronic pancreatitis, and K-ras gene mutation detected in pancreatic juice. Gastroenterology 1997; 113: 5593-5598.
14. GANSAUGE S, SCHMIDT RM, MULLER J, ADLER G, MATTFELDT T, BEGER HG. Genetic alterations in chronic pancreatitis: Evidence of early occurence of p53 but not K-ras mutations. Br J Surg 1998; 85: 337-340.
15. GARTEL AL, TYNER AL. Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res 1999; 246: 280-289.
16. GOLD EB, GORDIS L, DIENER MD, SELTSER R, BOINOTT JK, BYNUM TE. Diet and other risk factors for cancer of the pancreas. Cancer 1985; 55: 460-467.
17. WAF1/CIP1 in pancreatic cancer. Brit J Cancer 1997; 76: 299-305.
18. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
19. HRUBAN RH, ADSAY NV, ALBORES-SAAVEDRA J, COMPTON C, GARETT ES, GOODMAN SN, KERN SE, KLIMSTRA DS, KLOPPEL G, LONGNECKER DS, LUTTGES J, OFFERHAUS GJA. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Path 2001; 25: 579-586.
20. HRUBAN RH, MANSFELD ADM, OFFERHAUS GJA, WEERING DHJ, ALLISON DC, GOODMAN SN, KENSLER TW, BOSE KK, CAMERON JL, BOS JL. K-ras Oncogene Activation in Adenocarcinoma of the Human Pancreas. Am J Pathol 1993; 143: 545-553.
21. HRUBAN RH, WILENZ RE, KERN SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825.
22. HRUBAN RH, YEO CJ, KERN SE. Pancreatic Cancer. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill, 1996: 603-613.
23. WAF1/CIP1 expression and growth inhibition in human carcinoma cells. Cancer Res 1998; 58: 5656-5661.
24. KARLSON BM, EKBOM A, JOSEFSSON S, MCLAUGHLIN LK, FRAUMENI JF JR, NYREN O. The risk of pancreatic cancer folowing pancreatitis: An association due to confounding? Gastroenterology 1997; 113: 587-592.
25. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B, CRAIG RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
26. KASTAN MB, ZHAN Q, EL-DEIRY WS, CARRIER F, JACKS T, WALSH WV, PLUNKETT BS, VOGELSTEIN B, FORNACE AJ JR. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia teleangiectasia. Cell 1992; 71: 587-597.
27. KIMURA W, MORIKANE K, ESAKI Y, CHAN WC, POUR PM. Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinoma detected incidentally at autopsy. Cancer 1998; 82: 1839-1849.
28. KIVINEN L, TSUBARI M, HAAPAJARVI T, DATTO MB, WANG XF, LAIHO M. Ras induces p21WAF1/CIP1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene 1999; 18: 6252-6261.
29. LABAER J, GARETT MD, STAVENSON LF, SLINGERLAND JM, SANDHU C, CHOU HS, FATTAEY Y, HARLOW E. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847-862.
30. LEI S, APPERT HE, NAKATA B, DOMENICO DR, KIM K, HOWARD JM. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 1995; 17: 15-21.
31. LEMOINE NR, JAIN S, HUGHES CM, STADDON SL, MAILLET B, HAŮŮ PA, KLOPPEL G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102: 230-236.
32. LEVINE AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
33. LOWENFELS AB, MAISONNEUVE P, CAVALLINI G, AMMANN RW, LANKISCH PG, ANDERSEN JR, DIMAGNO EP, ANDREN-SANDBERG A, DOMELLOF L. Pancreatitis and the risk of pancreatic cancer. N Engl J med 1993; 328: 1433-1437.
34. LUTTGES J, DIETRICHS A, MENKE MA, VOGEL I, KREMER B, KLOPPEL G. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000; 88: 2495-2504.
35. MALANEY S, DALY R. The Ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 101-103.
36. NENUTIL R, VOJTESEK B. Physioloical levels of p53 protein in normal human tissue as detected using tyramide amplification (abstract). The Histochemical Journal 2001; 33: 231-251.
37. NOVOTNY J, KLEIBL Z, VEDRALOVA J, KOLAROVA M, PETRUZELKA L, JANKU F, MATOUS B. c-erbB-B2 expression and K-ras mutations in pancreatic cancer. Correlation with clinical course and pathological characteristics. Klin Onkol 2000; 13: 167-170.
38. ORTH M, GANSAUGE F, GANSAUGE S, BERGER HG, ADLER G, SCHMID RM. K-ras mutations at codon 12 are rare events in chronic pancreatitis. Digestion 1998; 59: 120-124.
39. PRIVES C, HALL PA. The p53 Pathway. J Pathol 1999; 187: 112-126.
40. SHERR SJ. Cancer cell cycles. Science (Wash. DC) 1996; 274: 1672-1677.
41. SMIT VTH, BOOT AJM, SMITS AMM, FLEUREN GJ, CORNELISSE CJ, BOS JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucl Acids Res 1988; 16: 7773-7782.
42. TADA M, OMATA M, OHTO M. Clinical implication of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991; 100: 233-238.
43. VELEMA JP, WALKER AM, GOLD EB. Alcohol and pancreatic cancer. Insufficient epidemiologic evidence for a causal relationship. Epidemiol Rev 1986; 8: 28-41.
44. VOGELSTEIN B, FEARON ER, HAMILTON SR, KERN SE, PREISINGER AC, LEPPERT M, NAKAMURA Y, WHITE R, SMITS AM, BOS JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
45. WILLIAMS TM, WINER DB, GREENE MI, MAGUIRE CH JR. Expression of c-erb-B2 in human pancreatic adenocarcinomas. Pathobiology 1991; 59: 46-52.
46. YOKOYAMA M, YAMANAKA Y, FRIESS H, BUCHLER M, KORC M. p53 expression in human pancreatic cancer correlates with enhanced biological agressiveness. Anticancer Res 1994; 14: 2477-2484.